Translating The Cancer Genome - Guest Editors

Dr. Elaine R. Mardis

Guest Editor, PLOS Medicine Translating the Cancer Genome.

Elaine Mardis is the co-director of the McDonnell Genome Institute at Washington University and the Robert E. and Louise F. Dunn Distinguished Professor of Medicine.

Dr. Mardis has a long-standing interest in the development of sequencing technologies, which, in the 1990s, led her to play a pivotal role in the completion of the Human Genome project. Driven by the desire to apply her technological know-how to the improvement of human health, she then pioneered the sequencing and analysis of cancer genomes. These milestones have established Elaine as a leader in the cancer genomics field.

Competing Interests: Dr. Mardis has a Supervisory Board membership at Qiagen NV, and has served on their board since 2014.  Dr. Mardis also serves on the Scientific Advisory Boards of Regeneron Pharmaceuticals Genomics Facility, DNANexus, ZS Genetics and Caperna.

Dr. Marc Ladanyi

Guest Editor, PLOS Medicine Translating the Cancer Genome.

Marc Ladanyi is Attending Pathologist and Chief of the Molecular Diagnostics Service and Member in the Human Oncology & Pathogenesis Program at Memorial Sloan Kettering Cancer Center (MSKCC).

Dr. Ladanyi is a molecular pathologist whose laboratory studies the genomics and molecular pathogenesis of sarcomas and thoracic malignancies, with an emphasis on genomic pathology/cancer genomics work on human cancer tissues and human cancer cell lines. The overall focus is on understanding pathobiology, improving molecular diagnosis, refining prognostication, and identifying new therapeutic targets. The approaches used include integrated genomics, functional genomic screens, chemical screens, and related single gene functional studies and pre-clinical studies. He has also been involved with the TCGA project since its inception in 2006, leading both data generation efforts at MSKCC and later co-leading data analysis efforts at MSKCC. He has played a major role in the TCGA Network papers on glioblastoma, squamous lung cancer, and lung adenocarcinoma, among others, and is currently co-chair of the TCGA analysis working groups for sarcoma and pleural mesothelioma. On the clinical side, as Chief of Molecular Diagnostics Service at MSKCC, he oversees large scale prospective clinical genomic testing.

Competing Interests: Dr. Ladanyi serves on an NCCN/Boehringer Ingelheim Afatinib grants program advisory committee.